$11M Goes to Study Genetics of IPF in Families

Idiopathic pulmonary fibrosis (IPF) is a disease that causes scarring in the lungs and serious shortness of breath. While there is currently no known cure for IPF, there are treatments available to help ease the symptoms. A research group at the Lulu Owen School of Medicine based at…

Pulmonary rehabilitation through exercise can help patients with chronic lung diseases such as pulmonary fibrosis breathe better. Read about nine steps to better manage pulmonary fibrosis. In this UHN Patient Education video shared in November 2014 let Dr. Ken Chapman, the director of the Pulmonary Rehab Program at…

In this TedEd video shared in November 2014, watch Emma Bryce’s informative lesson about how our lungs work. Want to know more about lungs? Read 8 cool facts here.  Breathing occurs 15-25 times a minute and the average person will inhale 10,000 liters of air each day. Sound…

Boehringer Ingelheim recently held a second regional respiratory conference concerning the latest medical and scientific insights on the treatment and management of respiratory diseases — namely, pulmonary fibrosis, chronic obstructive pulmonary disease (COPD) and asthma. These conditions represent a major public health problem in developing countries, due to their high incidence, and their…

With this Loyola Medicine video, hear a candid report from Dr. Daniel Dilling, medical director of Loyola’s lung transplant program, and patient Diane Williams about Diane’s long-awaited lung transplant. Learn more about some of the myths about lung transplantations. Diane is a retired special education teacher who had always enjoyed a high-energy…

Physical inactivity and low blood-oxygen levels during periods of exercise predict poor survival in patients with idiopathic pulmonary fibrosis (IPF), according to researchers at the Rabin Medical Center in Israel. The study, “Physical Activity and Exertional Desaturation Are Associated with Mortality in Idiopathic Pulmonary Fibrosis,” published in the Journal of…

Researchers are one step closer to understanding the molecular mechanism of action of pirfenidone, the anti fibrotic drug for the treatment of pulmonary fibrosis. This may help improve the safety and efficacy of the drug, which is often used in very high doses to achieve therapeutic effectiveness, causing a range of adverse side effects.

The Duke Clinical Research Institute (DCRI) and Boehringer Ingelheim Pharmaceuticals are expanding the Idiopathic Pulmonary Fibrosis – PROspective Outcomes (IPF-PRO) Registry, an academic-industry alliance between the two to better understand outcomes and disease progression in people with idiopathic pulmonary fibrosis (IPF), a rare lung disease. The expansion will…

Coughing and shortness of breath are main symptoms and complications of a condition called idiopathic pulmonary fibrosis (IPF). IPF is a subcategory of pulmonary fibrosis, a lung disease that causes scarring of the lungs which makes breathing difficult. IPF has no known cause and no current available cure, although some treatment options exist to ease…

Coughing and shortness of breath are the main symptoms and complications of a condition called idiopathic pulmonary fibrosis (IPF). IPF is a subcategory of pulmonary fibrosis, a chronic and typically progressive scarring lung disease. Some patients live many years with this disease, while some may have a shorter life with it.